MARKET

TNXP

TNXP

Tonix Pharmaceut
NASDAQ
0.3749
+0.0049
+1.32%
Closed 19:52 12/08 EST
OPEN
0.3742
PREV CLOSE
0.3700
HIGH
0.3766
LOW
0.3650
VOLUME
966.70K
TURNOVER
--
52 WEEK HIGH
14.36
52 WEEK LOW
0.3600
MARKET CAP
21.57M
P/E (TTM)
-0.0667
1D
5D
1M
3M
1Y
5Y
TNXP: Six Phase 2 or 3 Studies for CNS Programs Expected in the Clinic by 1Q23
By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update Up to Six Phase 2 or 3 Studies for CNS Programs Expected in the Clinic by 1Q23 Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has built a diverse pipeline that includes d...
Zacks Small Cap Research · 3d ago
BRIEF-Tonix Pharmaceuticals Announces Collaboration With Boston Children’S Hospital
Reuters · 3d ago
Tonix Pharmaceuticals Announces Collaboration With Boston Children's Hospital To Study TNX-1500 For Prevention Of Graft-versus-Host Disease Following Hematopoietic Stem Cell Transplantation In Animals
Benzinga · 3d ago
Tonix Collaborates with Boston Children's Hospital to Study TNX-1500 for Prevention of Graft-versus-Host Disease in Animals
Tonix Collaborates with Boston Children's Hospital to Study TNX-1500 for Prevention of Graft-versus-Host Disease in Animals
MT Newswires · 4d ago
Health And Human Services Issues Statement On Mpox; Says Does Not Expect That It Needs To Renew The Emergency Declaration When It Ends On January 31, 2023
Benzinga · 6d ago
BRIEF-Tonix Pharmaceuticals Presents Development Update On Potential Smallpox And Monkeypox Vaccine
Reuters · 12/01 12:24
Tonix Pharmaceuticals Presents Development Update on Potential Smallpox and Monkeypox Vaccine TNX-801 in an Oral Presentation at the World Vaccine and Immunotherapy Congress
TNX-801 is Based on the Sequence of a Natural Isolate of Horsepox and is Believed Closer in Structure to Edward Jenner’s 1798 Vaccine than Modern Vaccinia Virus Vaccines Against Smallpox Live-Virus Vaccine Platform Leverages Tonix’s Expanding Internal Deve...
GlobeNewswire · 12/01 12:00
Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress
Research Being Conducted in Collaboration with Scientists at Columbia University SARS-CoV-2 Variants have Evaded Antibody Therapeutics Previously Granted FDA Emergency Use Authorization, but which are No Longer Recommended for Use by the NIH COVID-19 Guide...
GlobeNewswire · 11/30 12:00
More
About TNXP
Tonix Pharmaceuticals Holding Corp. (Tonix) is a clinical-stage biopharmaceutical company. It is focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonixs portfolio is primarily composed of immunology and central nervous system (CNS) and infectious disease product candidates. Its immunology portfolio includes biologics to address organ transplant rejection, autoimmune diseases, and cancer. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Its infectious disease portfolio of product candidates includes vaccines to prevent COVID-19, an antiviral to treat COVID-19, and treatment for long COVID. The infectious disease portfolio also includes a vaccine in development to prevent smallpox and monkeypox. Its product candidates include TNX-1500, TNX-1300, TNX-102 SL, TNX-102 SL, TNX-102 SL,TNX-1900,TNX-601 CR, and TNX-1900.

Webull offers kinds of Tonix Pharmaceuticals Holding Corp stock information, including NASDAQ:TNXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNXP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TNXP stock methods without spending real money on the virtual paper trading platform.